antiviral news

Press Releases in the global landscape
Sep 27, 2023

About 250,000 courses of COVID pill Paxlovid being administered per week - Pfizer CEO

Pfizer Inc's chief executive said on Tuesday that almost 250,000 courses of the drugmaker's oral antiviral COVID-19 treatment Paxlovid were being administered per week as cases surged in the United States.
Read More »
Sep 27, 2023

Medication and mutations: molnupiravir's impact on SARS-CoV-2 genomes

Researchers discovered molnupiravir-associated mutational signatures in SARS-CoV-2 genomes.
Read More »
Sep 25, 2023

Covid-19 drug may be creating new variants with distinctive mutations

Covid-19 viruses with distinctive patterns of mutation are appearing in countries that use a drug called molnupiravir, however, none of these is a variant of concern.
Read More »
Sep 25, 2023

Covid antiviral drug linked to ‘transmissible’ mutations, research finds

Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient.
Read More »
Sep 25, 2023

First antiviral drug for Covid may have created mutations, scientists find

First antiviral drug for Covid may have created mutations, scientists find.
Read More »
Sep 22, 2023

Paxlovid Weaker Against Current COVID-19 Variants

A real-world study found that Pfizer's COVID-19 antiviral Paxlovid is now less effective at preventing hospitalization or death in high-risk patients as compared with earlier studies.
Read More »